UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Appropriate empirical antibiotic therapy and mortality: Conflicting data explained by residual confounding

PloS one, 2019-11, Vol.14 (11), p.e0225478-e0225478

2019

Volltextzugriff (PDF)

Time–kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis

Journal of antimicrobial chemotherapy, 2010-12, Vol.65 (12), p.2582-2589

2010

Volltextzugriff (PDF)

Delamanid or pretomanid? A Solomonic judgement

Journal of antimicrobial chemotherapy, 2022-03, Vol.77 (4), p.880-902

2022

Volltextzugriff (PDF)

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data

The Journal of infectious diseases, 2022-06, Vol.225 (11), p.1876-1885

2022

Volltextzugriff (PDF)

Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model

The Journal of infectious diseases, 2021-09, Vol.224 (6), p.1039-1047

2021

Volltextzugriff (PDF)

Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases

Frontiers in immunology, 2017-04, Vol.8, p.294-294

2017

Volltextzugriff (PDF)

Mycobacterium tuberculosis clinical isolates of the Beijing and East-African Indian lineage induce fundamentally different host responses in mice compared to H37Rv

Scientific reports, 2019-12, Vol.9 (1), p.19922-11, Article 19922

2019

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro , in vivo methodologies and human studies

Frontiers in pharmacology, 2022-12, Vol.13, p.1063453-1063453

2022

Volltextzugriff (PDF)

Consequences of Noncompliance for Therapy Efficacy and Emergence of Resistance in Murine Tuberculosis Caused by the Beijing Genotype of Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy, 2012-09, Vol.56 (9), p.4937-4944

2012

Volltextzugriff (PDF)

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model

Antimicrobial agents and chemotherapy, 2018-09, Vol.62 (9)

2018

Volltextzugriff (PDF)

Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain

Antimicrobial agents and chemotherapy, 2017-10, Vol.61 (10)

2017

Volltextzugriff (PDF)

Improving treatment outcome assessment in a mouse tuberculosis model

Scientific reports, 2018-04, Vol.8 (1), p.5714-9, Article 5714

2018

Volltextzugriff (PDF)

Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model

American journal of respiratory and critical care medicine, 2013-05, Vol.187 (10), p.1127-1134

2013

Volltextzugriff (PDF)

Tuberculosis mimicking ileocecal intussusception in a 5-month-old girl

Pediatrics (Evanston), 2008-05, Vol.121 (5), p.e1434

2008

Volltextzugriff (PDF)

Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models

CPT: pharmacometrics and systems pharmacology, 2017-11, Vol.6 (11), p.787-797

2017

Volltextzugriff (PDF)

Treatment and Outcome of Culture-Confirmed Mycobacterium marinum Disease

Open forum infectious diseases, 2022-04, Vol.9 (4), p.ofac077-ofac077

2022

Volltextzugriff (PDF)

Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus

Journal of antimicrobial chemotherapy, 2019-10, Vol.74 (10), p.2930-2933

2019

Volltextzugriff (PDF)

Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro

Antimicrobial agents and chemotherapy, 2016-04, Vol.60 (4), p.2577-2579

2016

Volltextzugriff (PDF)

Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis

Tuberculosis (Edinburgh, Scotland), 2013-01, Vol.93 (1), p.96-101

2013

Volltextzugriff (PDF)

Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice

Journal of antimicrobial chemotherapy, 2007-11, Vol.60 (5), p.1064-1073

2007

Volltextzugriff (PDF)

Less Is More: When to Repeat Antimicrobial Susceptibility Testing

Journal of clinical microbiology, 2023-08, Vol.61 (8), p.e0046323-e0046323

2023

Volltextzugriff (PDF)

Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB

Emerging infectious diseases, 2012-04, Vol.18 (4), p.660-663

2012

Volltextzugriff (PDF)

Relative Contributions of the Novel Diarylquinoline TBAJ-876 and its Active Metabolite to the Bactericidal Activity in a Murine Model of Tuberculosis

The Journal of infectious diseases, 2024-06

2024

Volltextzugriff (PDF)

The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid

Clinical microbiology and infection, 2022-08, Vol.28 (8), p.1047-1049

2022

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(46)
Berichte
(1)

Sprache

Englisch
(47)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(37)
Microbiology
(23)
Infectious Diseases
(21)
Tuberculosis
(21)
Antitubercular Agents - Pharmacology
(18)
Humans
(18)
Mycobacterium Tuberculosis
(17)
Mycobacterium Tuberculosis - Drug Effects
(16)
Pharmacology & Pharmacy
(16)
Animals
(13)
Female
(13)
Tuberculosis - Drug Therapy
(12)
Immunology
(11)
Antitubercular Agents - Therapeutic Use
(10)
Microbial Sensitivity Tests
(10)
Disease Models, Animal
(9)
Mice
(9)
Mice, Inbred Balb C
(9)
Respiratory System
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Appropriate empirical antibiotic therapy and mortality: Conflicting data explained by residual confounding

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Time–kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis

Delamanid or pretomanid? A Solomonic judgement

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data

Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model

Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases

Mycobacterium tuberculosis clinical isolates of the Beijing and East-African Indian lineage induce fundamentally different host responses in mice compared to H37Rv

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro , in vivo methodologies and human studies

Consequences of Noncompliance for Therapy Efficacy and Emergence of Resistance in Murine Tuberculosis Caused by the Beijing Genotype of Mycobacterium tuberculosis

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model

Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain

Improving treatment outcome assessment in a mouse tuberculosis model

Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model

Tuberculosis mimicking ileocecal intussusception in a 5-month-old girl

Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models

Treatment and Outcome of Culture-Confirmed Mycobacterium marinum Disease

Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus

Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro

Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis

Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice

Less Is More: When to Repeat Antimicrobial Susceptibility Testing

Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB

Relative Contributions of the Novel Diarylquinoline TBAJ-876 and its Active Metabolite to the Bactericidal Activity in a Murine Model of Tuberculosis

The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid

Suchergebnisse filtern